Flu jab – convenient, safe and long-term
Strictly speaking, the ‘choked’, i.e., inactivated three viruses (A1, A2, B) in the new vaccine will be the same as before. They are included in the vaccine composition on the recommendation of the World Health Organisation. But the additional substances, however, proposed by the researchers, are what make it possible to make this vaccine in tablet form. What is more, believe the authors, this vaccine will be more efficient than all known equivalents. Not because an injection is replaced with a tablet, but because the authors propose to include a so-called adjuvant into the vaccine composition; put simply – an enhancer for the effect of the vaccine. The scientists are already confident of its effectiveness: A similar, intranasal vaccine which they developed previously (what specialists call nasal drops) with the same adjuvant is already at clinical trial stage. The first volunteers will be testing it in the first clinical trials this autumn.
So, the most important component of this vaccine is Korauban, an original immunostimulant, or a substance that intensifies immunity. Its correct name is a stimulant of immunogenesis, a gamma-interferon inductor. This is a close relative of regular cellulose; the same polysaccharide, only of a slightly different structure. It is produced by ‘specially trained’ microorganisms and it serves to enhance the action of the vaccine.
Korauban, if we are to greatly simplify the matter, calls special cells, which are to eliminate alien elements, to where the decontaminated virus has struck, and it presents the enemy to them. As a result the organism strenuously produces protection – special proteins (antibodies) and cells, both directed to the form of the enemy. What is of especial importance is that, as a result, humans produce so-called local cell immunity, of a long-term and wide-ranging action; not only against the used vaccine and existing epidemic viruses, but also against the pathogens of future epidemics. And in the region of the nose and throat. It is with damage to the latter, incidentally, that the illness begins. In the first days flu usually passes without a cold.
‘The combination of Korauban and vaccine viruses in one preparation leads to a synergy of their action,’ states Project manager Oleg Kuznetsov. ‘This is displayed in an increase in early synthesis of common interferon, a factor of the synthesis of intensified non-specific resistance of the organism to bacterial and viral infections. Obviously the preparation could be applied for emergency protection not only from flu but also from other acute respiratory viral infections. Such a protection would suffice for a week; further, a specific protection against flu will begin to act’.
Finally, there is another substance in the composition of the tablet, which ensures the tablet-vaccine remains stable for a 12-month period. The scientists will obtain the first clinical test results no earlier than next Spring. For now it will be in the form of drops in aerosol form and not tablets. However, the authors are confident of its success. The vaccine demonstrated high efficiency on laboratory animals and proved to be completely non-toxic. The researchers believe that this ‘jab’ will need to be taken once every few years. The sooner the better.
Andrew Vakhliaev | alfa
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...